Total hip or knee arthroplasty is associated with significant blood loss. Techniques such as the use of antifibrinolytics or desmopressin, or normovolaemic haemodilution have been used to reduce the need for allogeneic blood transfusion. Tranexamic acid has been used to reduce blood loss and transfusion requirement for total hip and knee arthroplasty, with variable results. This meta-analysis aims to evaluate whether intravenous tranexamic acid, when compared with placebo, reduces blood loss and transfusion requirement in total hip and knee joint replacement surgery and whether it might increase the risk of thromboembolic complications. The literature search was based on MEDLINE, EMBASE, Cochrane Controlled Trials Register, and information from the pharmaceutical company that produces tranexamic acid (Pharmacia-Upjohn). We identified 15 clinical trials and 12 were considered suitable for detailed data extraction. Tranexamic acid reduces the proportion of patients requiring allogeneic blood transfusion (OR 0.16,, total amount of blood loss (WMD 460 ml,, and the total number of units of allogeneic blood transfused (WMD 0.85 unit,. Tranexamic acid does not increase the risk of thromboemobolic complications such as deep vein thrombosis, pulmonary embolism, thrombotic cerebral vascular accident, or myocardial infarction (OR 0.98,. Intravenous tranexamic acid appears effective and safe in reducing allogeneic blood transfusion and blood loss in total hip and knee arthroplasty.
The use of a pneumatic tourniquet and implantation of prostheses under ischaemic conditions such as during total knee arthroplasty induces a significant activation of coagulation and fibrinolysis at a regional level. This results in significant blood loss requiring allogeneic blood transfusion 1, 2 . Allogeneic blood transfusion is, however, not free of risk. Risks include infective complications, immune sensitization and reaction, over-transfusion, and coagulopathy. A number of methods have been suggested as a means of reducing blood loss and hence allogeneic blood transfusion. Pharmacological methods such as anti-fibrinolytic drugs, desmopressin (DDAVP) and erythropoietin have been advocated in the perioperative setting 3, 4 .
Tranexamic acid is a synthetic derivative of the amino acid lysine and a competitive inhibitor of plasminogen activation, and therefore interferes with fibrinolysis. It has been used, with variable results, in the setting of cardiac surgery and artificial joint replacement to minimize allogeneic blood transfusion 1, 2, [5] [6] [7] . Compared with other anti-fibrinolytic drugs, tranexamic acid is much cheaper than aprotinin and much more potent than aminocaproic acid 7 . Also, tranexamic acid penetrates very well into major joints, producing a drug concentration in joint fluid comparable to the serum drug concentration 8 . A previous meta-analysis that included all types of surgery demonstrated a beneficial effect of tranexamic acid in the perioperative setting, although the raw data involving orthopedic surgery was limited. All individual trials were small and under-powered for the detection of both clinical effectiveness and complications 7 . There have been eight more clinical trials involving the use of tranexamic acid in hip and knee arthroplasty surgery since the publication of that meta-analysis. We decided to analyse all the trials, to determine the clinical effectiveness and safety of intravenous tranexamic acid for patients undergoing elective artificial total hip or knee joint replacement surgery. We included patients undergoing either hip or knee joint arthroplasty because the underlying mechanism of bleeding is likely to be similar 1, 6 and because deep vein thrombosis is a concern common to both types of surgery.
METHODS
In this meta-analysis we included only randomized controlled trials involving elective or non-emergency hip and knee joint replacement surgery. The intervention considered was intravenous tranexamic acid. Studies involving administration of tranexamic acid by oral or intramuscular route were excluded. Studies that involved a combination of more than one active intervention were included if both intervention and control groups were exposed to the other active intervention. Trials that compared intravenous tranexamic acid with another active intervention, such as 1-deamino-8-D-arginine vasopressin (DDAVP), but without a separate placebo group, were excluded. Trials that involved significant intervention not given to both groups, such as if one group received perioperative heparin prophylaxis and the other group did not, were excluded.
The main outcomes measured were the proportion of patients receiving allogeneic blood transfusion, the proportion with thromboembolic complications, the total blood loss at 24 hours after surgery or until removal of the surgical drain, and the average number of units of blood transfused per patient. The presence of postoperative complications such as deep vein thrombosis/pulmonary embolism/myocardial infarction/cerebral vascular accident was defined by venography or ultrasound, computer tomography pulmonary angiography (CTPA) scan, elevated serum troponin level, and CT head respectively.
This review retrieved articles that were included in the electronic databases OVID MEDLINE and EMBASE (from January 1966 to December 1, 2002) , Current Contents, and the Cochrane Controlled Trials Register (2002, Issue 4). During the electronic database search, the following exploded MeSH terms were used: "tranexamic acid", "transfusion", "hemorrhage", and "anesthesia", "hip", "knee". Also, the following text-words terms were included: transamin, transfus$, bleed$, blood loss$, hemorrhag$, knee$, hip$. The reference lists of related reviews and original articles identified were checked for relevant trials. The pharmaceutical company (Pharmacia-Upjohn) producing intravenous tranexamic acid (Cyklokapron ®) was also contacted to confirm that no data or randomized trial had been missed for this meta-analysis. Whenever possible and necessary, the authors of the identified trials were contacted to obtain additional vital information and unpublished data.
Two independent reviewers examined the titles and the abstracts of all trials identified, to confirm that they had fulfilled the inclusion criteria. They also examined and recorded the trial characteristics and outcomes independently, using a pre-designed data abstraction form. This form was used to record information regarding the quality of the trial, such as allocation concealment, randomization method, blinding of treatment, inclusion and exclusion criteria. The grading of allocation concealment was based on the Cochrane approach, i.e. adequate, uncertain or clearly inadequate. If there was uncertainty about any of the above vital information, authors of the trials were contacted for more information or clarification. Any disagreements between the two independent reviewers were resolved by consensus. Any duplicated publications were combined to represent one single trial. In addition to the major outcome measures, the following data were also recorded if available. These were total length of hospital stay, hospital mortality and economic analysis. Use of other blood products such as fresh frozen plasma and/or platelet concentrates were recorded if available. Data were checked and entered into Review Manager database (RevMan version 4.1, The Cochrane Collaboration 2000) by two independent reviewers and the results crossed checked.
Summary statistics for the binary outcomes such as proportions of patients requiring allogeneic blood transfusion and having postoperative thromboembolic complications were presented as odds ratios using random effect model. Continuous outcome variables such as total volume of blood loss per patient and average number of units of allogeneic blood transfused per patient were presented as weight mean difference (WMD) using random effect model. WMD was calculated by the mean difference in blood loss in millilitres or units of blood transfused between the treatment group and the placebo group, adjusted according to the weight of individual studies. If only the median and range were reported in the original studies but the data were nearly normally distributed, the median was assigned as the mean and the standard deviation estimated as (0.95 X range)/4. If the data were not close to normal distribution, the trial results were not pooled for analysis. The presence of heterogeneity between trials was assessed by the Chi-square statistic and data were further analysed to explore the possible reasons for the heterogeneity.
Sensitivity analyses were performed to test the robustness of the results. These included analyses after excluding trials with unknown or inadequate allocation concealment or blinding of randomization, separate analyses of hip and knee arthroplasty studies, and subgroup analysis of those trials using regional anaesthesia techniques alone. Funnel plots were used to detect potential publication bias.
RESULTS
The search identified 15 clinical trials of which 12
were considered suitable for detailed data extraction and further analysis ( Figure 1 ). Two studies were excluded because of lack of a control placebo group 9-10 .
One study was excluded because it was a subgroup analysis of another study that had already been included 11 . In the 12 studies included, eight involved knee arthroplasty 1,2,5,12-16 , three hip arthroplasty 6, 17, 18 , and one had two intervention groups with two control groups, studying both total hip and knee arthroplasty 19 . The mean age of all the patients in these studies ranged from 65 to 75 years old. Four studies used tranexamic acid before skin incision, six studies before deflation of the tourniquet in total knee arthroplasty, and two studies either before skin incision or before tourniquet deflation in different subgroups of patients. acid in the postoperative period. The total dose of tranexamic acid was variable (range 10 mg.kg -1 to 135 mg.kg -1 , mean dose of all studies 41 mg.kg -1 , median 25 mg.kg -1 ). The regimen of two intravenous boluses (10-15 mg.kg -1 ) three hours apart was used in eight studies. Two studies used a single bolus and two a prolonged infusion or repeated boluses. We could not verify the regimen of deep vein thrombosis prophylaxis used in one study but the remaining 11 studies used low molecular weight heparin the night before surgery and daily after the surgery. Seven of 12 studies had adequate allocation concealment. All studies used an objective standardised transfusion trigger (e.g. haemoglobin level <10 g.dl -1 or haematocrit <30%) for their patients, although the triggers differed slightly between studies. Eleven studies 533 TRANEXAMIC ACID TO REDUCE BLOOD LOSS ] measured the total blood loss based on intraoperative blood loss plus the total surgical drain output until the drain was removed. Only one study estimated the concealed blood loss by measuring the size of the intramuscular haematoma with ultrasonography. There was good overall consistency in the effect of the tranexamic acid across the studies, with a significant reduction in the proportion of patients requiring allogeneic blood transfusion after treatment with intravenous tranexamic acid (OR 0.16, 95% CI: 0.09-0.26, P<0.00001) (Figure 2 ).
There was no significant increase in risk of thromboembolic complications associated with tranexamic acid (OR 0.98, 95% CI: 0.45-2.12, P=0.99) (Figure3). There was a significant reduction in the number of units of allogeneic blood transfused per patient (WMD 0.85 units, 95% CI: 0.36-1.33, P=0.0006) (Figure 4 ) and in the average amount of blood loss per patient (WMD 460 ml, 95% CI: 274-626, P<0.00001) ( Figure 5 ). However, there was signifi-cant heterogeneity in the results of these two continuous outcome variables. This is likely to be due to the very different baseline blood loss in the control groups in different studies. Different study populations, surgical and anaesthetic techniques, may account for this variability in blood loss. Also, the extent of bleeding may be concealed, because intramuscular haematoma and the total blood loss were measured at different times after the operation, depending on the time the surgical drain was removed (range 24 to 72 hours). Sensitivity analyses involving separation of hip from knee surgery studies, studies using regional versus general anaesthetic technique; exclusion of a study with delayed administration of tranexamic acid, or exclusion of studies with no allocation concealment, did not change the direction and magnitude of the treatment effect or account for the heterogeneity.
Only one study each reported the overall hospital mortality 5 and total hospital stay 14 and there was no difference between the treatment and control groups in these studies. Cost comparison involving only the cost of blood products and the drug cost was performed in two studies 12, 18 and favoured use of the drug.
DISCUSSION
Our results showed that intravenous tranexamic acid is effective (OR 0.16, 95% CI: 0.09-0.26) in reducing the requirement of allogeneic blood transfusion in total hip and knee arthroplasty. The regimen of two intravenous boluses (10-15 mg.kg -1 ), the first one given before deflation of tourniquet or skin incision and the second one three hours later, was used in eight of the 12 studies included. The true magnitude of the treatment effect may be slightly less than the summary statistics if the possible effect of publication bias is considered. The funnel plot for the transfusion outcome is suggestive of a small publication bias, mainly due to the absence of small negative studies ( Figure 6 ). The direction of the treatment effect is unlikely to be affected by this bias but the true magnitude of treatment effect may be slightly less than the reported average odds ratio. Statistical adjustment by methods such as "trim and fill" and "fail-safe N" have been proposed but it is still questionable whether such methods improve the overall accuracy of the summary statistics of a metaanalysis 20, 21 .
There were significant variations in the amount of bleeding and transfusion rates in different studies. This is likely to be related to the different surgical techniques and transfusion thresholds used in different clinical settings. As a result, the number needed to treat (NNT) for tranexamic acid to avoid transfusing one patient is variable. If the transfusion 535 TRANEXAMIC ACID TO rate in the control group is 10% then the NNT for tranexamic acid to avoid transfusing one patient with allogeneic blood in total hip and knee arthroplasty will be 20. On the other hand, if the transfusion rate is higher, for example 90%, then the NNT will only be 3. Therefore, tranexamic acid is likely to be more useful in the clinical setting of a high transfusion rate. Revision arthroplasty surgery is usually associated with a larger volume of blood loss and transfusion requirement. There is little literature about tranexamic acid in revision hip or knee joint arthroplasty but this would be worth further investigation. Also, tranexamic acid with other techniques of blood conservation may be useful in the management of patients with religious or other medical contraindications to blood transfusion, who undergo hip and knee arthroplasty. Accurate pharmaco-economic analysis of tranexamic acid usage is difficult because of the variable transfusion rates and the variable cost of a unit of allogeneic blood in different parts of the world. There were two studies 12, 18 reporting favourable cost reduction associated with use of tranexamic acid in hip and knee arthroplasty. However, indirect costs such as treatment costs for the side-effects of allogeneic transfusion or tranexamic acid (e.g. nausea and vomiting) were not included in the economic analyses of these two studies. Based on the summary data of this meta-analysis, tranexamic acid appears to be cost effective in New Zealand. The total drug cost of tranexamic acid (25 mg.kg -1 =NZ$59) is much less than the production cost of a unit of allogeneic blood (NZ$158) and the drug is not associated with an increase in major side effects that require expensive treatment. When the cost of tranexamic acid to avoid transfusing a unit of allogeneic blood is compared with other techniques of blood conservation such as aprotinin 7 , normovolaemic haemodilution 9,22 , erythropoietin 23 , preoperative autologous blood donation [24] [25] [26] and postoperative autotransfusion 27 , it also seems more cost-effective. Incorporating full pharmacoeconomic analysis in future randomized control trials involving different techniques of blood conservation will clarify this issue further.
The possibility of increasing the risk of thrombosis after the use of an antifibrinolytic agent in hip and knee arthroplasty surgery is a concern. The average baseline rate of thromboembolic complications in the control group of this meta-analysis was about 5.6%. The upper limit of the 95% confidence interval suggests that the absolute risk of thromboembolic complications in the treatment group could not be more than 11.6%, with no publication bias in reporting thromboembolic complications (Figure 7) . Also, there is some evidence that tranexamic acid works mainly by interfering with fibrinolysis in the wound, but not systemically 11, 14 . Therefore, the possibility of increased thromboembolic complications with tranexamic acid in total hip and knee arthroplasty is likely to be very small, if it exists. While tranexamic acid is considered to be contraindicated when there is a history of thromboembolic disease, increased risk of thromboembolism in patients without a history of thromboembolic disease has not been demonstrated when tranexamic acid is used in other clinical settings [28] [29] [30] .
In conclusion, intravenous tranexamic acid appears to be safe and effective in reducing allogeneic blood transfusion in patients undergoing primary total hip or knee arthroplasty. The clinical effectiveness is likely to be more significant in the setting of high transfusion rate. A comparison between tranexamic acid and other blood conservation techniques in revision hip or knee arthroplasty surgery when blood loss is more significant deserves further prospective randomized controlled trials.
